The purpose of this study is to compare two commonly used treatment choices for early-stage breast cancer in premenopausal women.
Learn more about the NRG-BR009 trial or call the Reading Hospital Cancer Research Office at 484-628-8193.
NRG-BR009
A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score ≤ 25 (OFSET).
